Mustang Bio Shares Are Trading Higher After the Company on Monday Announced Safety and Efficacy Data From the Complete Waldenstrom Macroglobulinemia Cohort of Its Phase 1/2 Clinical Trial of MB-106, Showing an Overall Response Rate of 90% With One...
Mustang Bio Shares Are Trading Higher After the Company on Monday Announced Safety and Efficacy Data From the Complete Waldenstrom Macroglobulinemia Cohort of Its Phase 1/2 Clinical Trial of MB-106, Showing an Overall Response Rate of 90% With One...
週一，Mustang Bio宣佈來自其第1/2期MB-106臨床試驗的完整Waldeström巨球蛋白血癥隊列的安全性和有效性數據，顯示90％的總反應率。1例患者仍在完全緩解狀態下。Mustang Bio股價上漲。
Mustang Bio Shares Are Trading Higher After the Company on Monday Announced Safety and Efficacy Data From the Complete Waldenstrom Macroglobulinemia Cohort of Its Phase 1/2 Clinical Trial of MB-106, Showing an Overall Response Rate of 90% With One Patient Remaining in Complete Remission at 31 Months.
Mustang Bio在週一宣佈了MB-106階段1/2臨床試驗的完整Waldenstrom大球蛋白血癥患者隊列的安全性和有效性數據，顯示出90%的總體應答率，其中有一名患者在31個月後仍然痊癒。股價因此有所上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。